Impact of drug alteration to maintain rhythm control in paroxysmal Atrial fibrillation: Subanalysis From J-RHYTHM Study

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 870-875

  Endo, Ayaka ^a   Kohsaka, Shun ^a   Suzuki, Shinya ^b   Atarashi, Hirotsugu ^c   Kamakura, Shiro ^d   Sakurai, Masayuki ^e   Nakaya, Haruaki ^f   Fukatani, Masahiko ^g   Mitamura, Hideo ^h   Yamazaki, Tsutomu ^b   Yamashita, Takeshi ⁱ   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e Hokko Memorial Hospital   (Japan)

^f CHIBA UNIVERSITY   (Japan)

^g Chikamori Hospital   (Japan)

^h SAISEIKAI CENTRAL HOSPITAL   (Japan)

ⁱ THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Outcome; Rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE; PIRMENOL; PROPAFENONE; SOTALOL;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RHYTHM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICAL DISABILITY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STROKE;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; EMBOLISM; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HEART RATE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; STROKE;

EID: 77951708270     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0643     Document Type: Article

References (14)

1. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electro- conversion of atrial fibrillation: A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284-290.
2. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920.
3. Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155: 1885-1891.
4. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: A comparative, placebo controlled study. Heart 2000; 84: 251-257.
5. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257.
6. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
7. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-741.
8. The therapeutic guideline for atrial fibrillation in Japan. Jpn Circ J 2001; 65(Suppl V): 931-978.
9. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. Am J Cardiol 1997; 79: 1198-1202.
10. Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008; 117: 1927-1935.
11. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
12. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
13. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al. Dose-Response Effects of Bepridil in Patients With Persistent Atrial Fibrillation Monitored With Transtelephonic Electrocardiograms. Circ J 2009; 73: 1020-1027.
14. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1973-1980.